Therapeutic window of antibody-based cancer immunotherapies

Immunotherapy is revolutionizing cancer treatment by stimulating and activating the immune system's killer cells to attack tumor cells. Despite the clinical success of antibody-based immune-therapeutics, notable limitations remain including differential responses between individuals and cancer types. Not all patients will respond to therapy and many cancer types are still incurable. Dose-limiting toxicity is another limiting factor for the efficacy of several drugs.  Further research is required to optimize therapies and improve outcomes. We are studying the mechanistic basis behind factors limiting immunotherapy in different mouse tumor models. We will utilize this knowledge to design improved drug platforms by applying different antibody engineering approaches.

Improving cancer immunotherapy